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Background.W eh a v ep r e v i o u s l ys h o w nad i ﬀerent local and systemic angiogenic proﬁle of CXC chemokines in Idiopathic
Pulmonary Fibrosis (IPF) patients compared to sarcoidosis. In particular, sarcoidosis showed an angiostatic microenvironment,
as compared with the angiogenic cytokine milieu seen in IPF. Purpose of the Study. Our aim was to further investigate the
aforementionedﬁndingbymeasuringtheexpressionofdiﬀerentchemokinesingranulomatousandﬁbroticdiseases.Weestimated
the levels of vascular endothelial growth factor (VEGF) and its high-aﬃnity receptor, Flt-1 (fms-like tyrosine kinase 1), in
bronchoalveolar lavage ﬂuid (BALF) of patients with IPF and pulmonary sarcoidosis. We have also investigated the mRNA
expression of angiogenetic chemokines’ receptors such as CXCR2 and CXCR3 and the biological axis of stromal derived factor-1α
(SDF-1α or CXCL12α/CXCL12β) and receptor, CXCR4. Methods. We studied prospectively three groups of patients: (i) one group
of 18 patients with IPF, (ii) one group of 16 patients with sarcoidosis, and (iii) 10 normal subjects. Results. A statistically signiﬁcant
increase has been detected in VEGF mRNA expression in IPF in comparison with pulmonary sarcoidosis (P = .03). In addition,
a signiﬁcant increase has been measured in CXCL12α in sarcoidosis in comparison to IPF (P = .02). Moreover, a statistically
signiﬁcantdecreasehasbeenfoundinFlt-1proteinlevelsinpulmonarysarcoidosisincomparisonwithIPF(P = .03).Asigniﬁcant
increase in VEGF (P = .03) and CXCR4 (P = .03) mRNA levels has been also detected in sarcoidosis’ patients when compared
withhealthycontrols.Conclusions.OurdatasuggestthatincreasedexpressionofFlt-1anddownregulationofCXCL12αinIPFmay
further support the hypothesis of a diﬀerent angiogenetic proﬁle between ﬁbrotic and granulomatous diseases. However, further
studies are needed in order to better investigate these enigmatic diseases.
Copyright © 2009 Katerina M. Antoniou et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Angiogenesis has been implicated in the pathogenesis of
several ﬁbrotic lung conditions, including idiopathic pul-
monary ﬁbrosis (IPF). This process plays a signiﬁcant role
in wound healing and contributes to the ﬁbroprolifera-
tion and extracellular matrix deposition [1]. Neovascular-
ization in ﬁbroproliferative disorders is regulated by an
opposing balance between angiogenic and angiostatic factors
[2, 3].
Sarcoidosis continues to be a disease of research interest
because of its complicated immune mechanisms and elusive
etiology [4]. So far, it has been established that granulo-
matous inﬂammation in sarcoidosis is predominately a T-
helper 1 immune response mediated by a complex network
of lymphocytes, macrophages, and cytokines [5]. The cause2 Clinical and Developmental Immunology
of progression to a chronic and potentially ﬁbrotic form is
still unclear and up to 30% of patients have chronic course of
thelungdisease,resultinginprogressivelossoflungfunction
[6, 7].
Recently the chemokine receptors expressed speciﬁcally
on Th1 cells were identiﬁed and it was reported that Th1
cells are characterized by the expression of CCR5 or CXC
chemokine receptor 3 [8]. While CXCR3/CXCR3 ligands
inhibit angiogenesis, CXCR3 ligands play a pivotal role in
orchestratingTh1cytokine-inducedcell-mediatedimmunity
via the recruitment of mononuclear and CD4+ T-cells
expressing CXCR3 and consequently via the granuloma
formation [4, 5]. So far, there are only few studies in the lit-
erature implicating angiogenesis in the immunomodulatory
cascade of sarcoidosis. BAL lymphocytes in sarcoidosis have
been reported to be highly positive for CCR5 and CXCR3
[9, 10]. Known ligands for CXCR3 are three angiostatic
ELR
−CXC chemokines (Mig/CXCL9, IP-10/CXCL10, and I-
TAC/CXCL11) [9–12]. Recent studies have shown that these
chemokines play an important role in the accumulation of
Th1 lymphocytes in sarcoid lungs [11]. We have shown that
sarcoidosis exhibits a distinct angiostatic proﬁle, as shown
by an ELR
−CXC chemokine upregulation in comparison
to IPF patients [12]. On the other hand, ELR+ CXC
chemokines (IL-8, ENA-78, and GRO-α) sharing the same
receptor, CXCR2, were found increased in IPF [12], while
a downregulation of their levels was recently shown after
treatment [13].
Vascular endothelial growth factor (VEGF) is a potent
growth factor for endothelial cells that regulates vascular
permeability and the stimulation of angiogenesis. VEGF is
crucial in lung development and maintenance during the
adult life. However, VEGF also contributes in several acute
and chronic lung disorders [14]. The biological activity of
VEGF depends on its reaction with speciﬁc receptors. Two
high aﬃnity receptors for VEGF have been described, Flt-1
(fms-like tyrosine kinase 1) and KDR/Flk-1 (fetal liver kinase
1) [14, 15].
We hypothesized that the levels of VEGF and receptor
Flt-1wouldbehigherinbronchoalveolarlavageﬂuid(BALF)
from patients with IPF than in patients with pulmonary
sarcoidosis. In order to further explore the angiogenetic
balance, we measured the mRNA levels of chemokines’
receptors, CXCR2 and CXCR3, as well as the biological axis
of CXCL12 and cognate receptor, CXCR4.
2. Patients
We studied prospectively three groups of patients: (i) 18
patients with IPF, (ii) 16 patients with sarcoidosis, and
(iii) 10 normal subjects. Patients’ and healthy controls’
characteristics are shown in Table 1.
The diagnosis of IPF was made in 8 cases by surgical
biopsy (in the correct clinical context, detailed below) and
the histologic diagnosis of Usual Interstitial Pneumonia
(UIP) was obtained. In the remaining 10 cases the diagnosis
was made on the basis of clinical and high-resolution
computed tomography (HRCT) criteria: (1) bilateral basal
Table 1: Demographic and lung function characteristics of patients
with IPF and Pulmonary Sarcoidosis. Values are expressed as mean
+ SD, and age as median (range).
Characteristics Sarcoidosis IPF Normal
subjects
Number 16 18 10
Sex (Male/Female) 6/10 14/4 5/5
Age median (yrs) 53 (30–64) 69 (56–83) 40 (27–62)
Smokers/ex- (3/0/13) (10/2/6) 0/0/10
smokers/Nonsmokers
FEV1 (% pred) 92.1±6.7 82.6±2.6 102±13
FVC (% pred) 94.7±6.2 76.2±2.4 103±19
TLC (% pred) 87.8±3.4 65.4±4.1 95±4
DLco (% pred) 95.1±3.1 52.2±6.1 96±6
PaO2 (mmHg) 80.2±5.7 71.5±2.8 85.5±3.1
TCC ×105 /mL 30.7±4.1 24.6±4.1 20.7±5.2
Macrophages% 70.1±8.2 86.1±2.6 94.2±1.3
Neutrophils % 3.2±3.8 6.8±2.1 3.7±2.2
Lymphocytes% 23.8±8.2 5.9±3.8 1.2±1.0
Eosinophils % 1.2±1.9 4.8±2.8 0.3±0.4
TCC: Total cell counts; FVC: Forced Vital Capacity; TLC: Total Lung
Capacity; DLCO:D i ﬀusing Capacity for Carbon Monoxide; PαO2:A r t e r i a l
Partial Pressure of Oxygen.
or widespread crackles, (2) restrictive ventilatory defect or
isolateddepressionofDLCO,(3)computedtomography(CT)
appearances indicative of IPF with predominantly basal
and subpleural microcystic or macrocystic honeycombing,
with variably extensive ground-glass and reticular abnor-
malities but no consolidation, nodular abnormalities, or
other parenchymal abnormalities (apart from centrilobular
emphysema), and (4) no environmental exposure to a ﬁbro-
genic agent or connective tissue disease [16]. According the
aforementioned criteria a known cause of pulmonary ﬁbro-
sis, such as a connective tissue disorder, has been excluded
bybothimmunologicscreeningandrheumatologicalclinical
evaluation.
Sarcoidosis diagnosis was made according to the
ATS/ERS/World Association of Sarcoidosis and Other Gran-
ulomatous Disorders joint statement [4]. All patients had
transbronchial or open lung biopsy with histopathological
evidence of noncaseating epithelioid cell granulomas with-
out evidence of infection or inorganic material to account
for the pulmonary granulomatous reaction. According to
chest radiographic classiﬁcation of sarcoidosis, 3 had stage
I disease (lymphadenopathy alone), 7 stage II disease (lym-
phadenopathy and parenchymal opacities), and 6 stage III
disease (only parenchymal opacities).
BALFwasalsoobtainedfromtenhealthycontrolpatients
without any past medical history, pulmonary symptoms, or
abnormal radiographical ﬁndings.
A former smoker was deﬁned as having smoked at least
one cigarette per day for 1 year: smoking histories were
collected as part of a routine prospective clinical protocol.Clinical and Developmental Immunology 3
Table 2: Primer sequences used for quantitative Real-time RT-PCR.
Growth factor or Cytokine Primer pair Sequence (5 -3 ) Annealing temperature Product size
VEGF ATGACGAGGGCCTGGAGTGTG 60
◦C9 1
CCTATGTGCTGGCCTTGGTGAG
FLT-1 CGGCGGCGGCGAACGAG 58
◦C 223
CATGATGTGCTGGGTGCCTTTTA
CXCL12α TGAGAGCTCGCTTTGAGTGA 55
◦C 233
CACCAGGACCTTCTGTGGAT
CXCL12β CTAGTCAAGTGCGTCCACGA 55
◦C 221
GGACACACCACAGCACAAAC
CXCR2 GGCCACTCCAATAACAGCAGGTC 60
◦C 197
GTAGAAAAGGGGGCAGGGTAGAGC
CXCR3 AAAGCAGAGGGGCAGGCAGCACAC 65
◦C 181
AGGGCGGGGAGGTACAGCACGAGT
CXCR4 GGTGGTCTATGTTGGCGTCT 55
◦C 229
TGGAGTGTGACAGCTTGGAG
Table 3: mRNA and protein expression of angiogenetic parameters
in IPF and Sarcoidosis. Values are expressed as mean ± SD.
Sarcoidosis IPF P value
VEGF-mRNA 2.99 ± 1.43 18.3 ± 14.9 .036
VEGF-protein 154 ± 36 344 ± 77 .202 (NS)
(pg/mL)
FLT-1-mRNA 204 ± 52 154 ± 33 .434 (NS)
FLT-1protein 3.0 ± 1.4 18.8 ± 6.5 .036
(pg/mL)
NS: Nonsigniﬁcant, P <.050 is considered statistically signiﬁcant
3. Methods
3.1. Pulmonary Function Tests. All patients were evaluated
spirometrically and by measurement of lung volumes, diﬀu-
sion capacity, and arterial blood gases (at rest). Spirometry
and lung volumes (helium-dilution technique) and TL,CO
(corrected for the haemoglobin) using the single-breath
method were performed by a computerised system (Jaeger
2.12; MasterLab, W¨ urzburg, Germany). Predicted values
were obtained from the standardised lung function testing
of the European Coal and Steel Community, Luxembourg
(1993) [17]. Arterial blood gases were measured by an
arterial blood gas analyser (AVL330; MasterLab system).
3.2. BAL Fluid Processing. BALF was obtained from patients
with IPF, sarcoidosis, and from normal healthy controls by
methods previously described [12, 13]. Brieﬂy, a ﬂexible
bronchoscope was wedged into a subsegmental bronchus of
a predetermined region of interest based on radiographical
ﬁndings. A BAL was performed by instilling a total of
240mL of normal saline in 60mL aliquots, each retrieved
by low suction. The BALF fractions were pooled and split
equally into two samples. One sample was sent to the
clinical microbiology and cytology laboratory and the other
sample was placed on ice and transported to the research
laboratory. The research sample was ﬁltered through sterile
gauze (Thompson, Ontario, Canada) and centrifuged at
400g for 15 minutes at 4◦C.
Total cell counts were determined using an improved
Neubauer counting chamber and expressed as the total
number of cells per mL of aspirated ﬂuid. The pellet
was washed three times with cold PBS-Dulbecco’s and the
cells were adjusted to a ﬁnal concentration of 106 cells/mL
with RPMI1640 plus 2% FCS. The slide preparation was
performed as previously reported [18]. The cell-free solution
wasaliquotedandfrozenimmediatelyat −80
◦Cuntilthawed
for chemokine ELISAs.
3.3. Assay of Chemokine Levels Using Speciﬁc Enzyme-
Linked Immunosorbent Assay. Human BALF protein levels
of VEGF-A and Flt-1 were quantitated according to the
manufacturer’s protocol using ELISA kits (R&D Systems)
andmeasurementswereperformedintheBALFsupernatant.
Human VEGF-A and Flt-1 had the lowest detectable limit of
5a n d1 0p g ·mL
−1,r e s p e c t i v e l y .
3.4. RNA Extraction and Reverse Transcription. Total RNA
was extracted form each specimen (BALF pellet) using a
power homogenizer and the TRIzol reagent (Invitrogen,
Carlsband, CA) according to the manufacturer’s instruc-
tions. cDNA was synthesized using the Strascript reverse
transcriptase kit (Stratagene, La Jolla, CA) as previously
described [19].
3.5. Real-Time RT-PCR. Peptide growth factors mRNA
expression was measured using a real-time RT-PCR assay
with SYBR-Green I. Primers were designed to span introns
[19]. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as the internal control, in order to normalize VEGF,
ﬂt-1, CXCR2, CXCR3, and both transcripts of CXCL12,
CXCL12α and β and CXCR4 expression levels (Table 2).
Speciﬁcally,1μL cDNAfrompathological or controlsamples
was ampliﬁed in a PCR reaction containing 2X Brilliant
SYBR-Green I QPCR Master Mix, 300nM of each primer4 Clinical and Developmental Immunology
Table 4: mRNA expression of VEGF, FLT-1 and angiogenetic chemokines in healthy subjects (Controls), Sarcoidosis (SARC) and IPF
patients. Values are expressed as mean ± SD.
Variables Controls IPF SARC P1v a l u e P2v a l u e P3v a l u e
VEGF 2.82 ± 3.6 18.3 ± 14.9 2.99 ± 1.43 NS .03 .03
Flt-1 134.6 ± 23.5 154.1 ± 33.5 204 ± 52 NS NS NS
CXCR2 0.001 ±0.002 0.08 ± 0.25 0.0004 ± 0.001 NS NS NS
CXCR3 0.03 ± 0.002 0.12 ± 0.39 0.0001 ± 0.0004 NS NS NS
CXCR4 0.86 ± 0.64 174.3±543.6 153.9 ± 129.3 NS .03 NS
CXCL12α 92.2 ± 132.17 168.5±576.7 1525.2 ± 2224.7 NS NS .02
CXCL12β 223.8 ± 176.6 142.4 ± 563.7 822.4 ± 1423.0 NS NS NS
NS: Non signiﬁcant, P < .050 is considered statistically signiﬁcant,
P1: P value between controls and IPF,
P2: P value between controls and Sarcoidosis,
P3: P value between IPF and Sarcoidosis.
and 30μM ROX passive reference dye, in a ﬁnal volume of
20μL. After an initial denaturation at 95
◦Cf o r1 0m i n u t e s ,
the samples were subjected to 40 cycles of ampliﬁcation,
comprised of denaturation at 95
◦C for 30 seconds, annealing
at appropriate temperature for each primer pair for 30
seconds and elongation at 72
◦C for 30 seconds, followed
by a melt curve analysis, in which the temperature was
increased from 55
◦Ct o9 5
◦C at a linear rate of 0.2
◦C/ s e c .
Data collection was performed both during annealing and
extension, with two measurements at each step, and at all
times during melt curve analysis. In each PCR reaction two
nontemplate controls were included. All PCR experiments
were conducted on the Mx3000P real-time PCR thermal
cycler using the software version 2.00, (Stratagene, La Jolla,
CA). To verify the results of the melt curve analysis, PCR
products were analyzed by electrophoresis in 2% agarose
gels, stained with ethidium bromide, and photographed on
a UV light transilluminator. Primer sequences, annealing
temperatures, and PCR products length for all the growth
factors analyzed, as well as for GAPDH, are described in
Table 2.
All reactions were run in triplicates, and peptide growth
factor transcript levels were calculated and normalized to
each specimen’s house keeping gene mRNA (GAPDH) as
well as the appropriate calibrators, using the ΔΔCt method
for relative quantiﬁcation. Speciﬁcally, after ampliﬁcation,
standard curves were constructed from samples used in a
series of consecutive dilutions, for both the gene of interest
(GF) and the internal control (GAPDH). Growth factor and
GAPDH ampliﬁcation eﬃciencies were the same, reaching
100%. IPF and sarcoidosis data were ﬁrst normalized
against variation in sample quality and quantity. Normalized
values to GAPDH, ΔCts, were initially calculated using the
following equation: ΔCtsample = CtGF −CtGAPDH.
4.StatisticalAnalysis
Peptide growth factors mRNA levels were ﬁrst evaluated by
the one-sample Kolmogorov-Smirnov goodness of ﬁt test,
in order to determine whether they follow a normal or
no distribution. Based on the results, the nonparametric
Spearmantestwasusedtoexaminecorrelations.Proportions
were compared using chi-square test. The Kruskal-Wallis
followed by a posthoc analysis for pairwise signiﬁcance and
the Mann-Whitney U test were used as indicated to examine
growth factors’ and chemokines’ expression status among
IPF and pulmonary sarcoidosis groups. Statistical analysis
was carried out using SPSS 13.0 Chicago IL, USA. Statistical
signiﬁcance was set at the 95% level (P-value < .05).
5. Results
The demographic and spirometric data of healthy controls,
IPF, and sarcoidosis’ patients are shown in Table 1.T o t a lc e l l
counts and cell diﬀerential were determined and shown in
Table 1.
5.1. VEGF Expression in mRNA and Protein Level. A statisti-
cally signiﬁcant increase has been detected in VEGF mRNA
expression in IPF in comparison with pulmonary sarcoidosis
(mean ± SD, 18.3 ± 14.9 versus 2.99 ± 1.43, P = .03,
resp.)(Table 3,Figure 1).However,nostatisticallysigniﬁcant
diﬀerencehasbeenmeasuredinVEGFproteinlevelsbetween
IPF and sarcoidosis patients (mean ± SD, 344 ± 77 versus
154 ± 36, P = .2), suggesting a posttranscriptional decrease
of mRNA expression (Table 3, Figure 2).
A statistically signiﬁcant increase has been detected in
VEGF mRNA expression in sarcoidosis in comparison with
healthy subjects (mean ± SD, 2.99 ± 1.43 versus 2.82 ± 3.62,
P = .03, resp.). No signiﬁcant diﬀerence has been detected
between IPF and control subjects (mean ± SD, 18.3 ± 14.9
versus 2.82 ± 3.62, P = .4, resp.) (Table 4).
5.2. Flt-1 Expression in mRNA and Protein Level. No sta-
tistically signiﬁcant diﬀerence has been measured in Flt-1
mRNA levels between IPF and sarcoidosis patients (mean ±
SD, 154 ± 33 versus 204 ± 52, P = .4) (Table 3, Figure 1).
A statistically signiﬁcant decrease has been detected in Flt-
1 protein expression in IPF in comparison with pulmonary
sarcoidosis(mean ±SD,18.8 ±6.5versus3.0 ±1.4,P = .036,
resp.), suggesting a posttranscriptional downregulation of
Flt-1 expression (Table 3, Figure 2).Clinical and Developmental Immunology 5
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Figure 1: mRNA expression of VEGF/ﬂt-1 in IPF versus Sarcoidosis.
Sarcoidosis IPF
P = .202
0
2
4
6
8
10
×102
12
−2
V
E
G
F
p
r
o
t
e
i
n
l
e
v
e
l
s
(a)
P = .036
Sarcoidosis IPF
0
20
40
60
80
−20
F
L
T
-
1
p
r
o
t
e
i
n
l
e
v
e
l
s
(b)
Figure 2: Protein expression of VEGF/Flt-1 in IPF versus Sarcoidosis.
No signiﬁcant diﬀerence has been measured between
healthy controls and sarcoidosis or IPF at ﬂt-1 mRNA
expression levels (Table 4).
5.3. Angiogenetic Chemokines (CXCR2, CXCR3, CXCR4, and
CXCL12α,C X C L 1 2 β) mRNA Expression Levels. A signiﬁcant
increase has been measured at CXCL12α in sarcoidosis’
patients in comparison with IPF samples (Table 4). We
have also detected that an increase, however, does not
reach statistical signiﬁcance (P = .06) at mRNA levels of
CXCR3 in IPF in comparison with sarcoidosis’ patients
(Table 4).
A statistically signiﬁcant increase has been detected in
CXCR4 mRNA expression in sarcoidosis in comparison with
healthy subjects (mean ± SD, 2.40 ± 1.02 versus 0.86 ± 0.64,
P = .03, resp.). However, no signiﬁcant diﬀerence has been
measuredbetweensarcoidosisandhealthycontrolsatmRNA
levels of the other chemokines (Table 4).6 Clinical and Developmental Immunology
A signiﬁcant increase has been detected in healthy
controls in comparison with IPF at CXCL12β mRNA levels
(mean ± SD, 223.8 ± 176.6 versus 141.9 ± 563.2, P = .03,
resp.).
6. Discussion
To the best of our knowledge this is the ﬁrst study to
investigate the local expression of the biological axis VEGF
and its receptor Flt-1 in patients with IPF and Pulmonary
Sarcoidosis without pulmonary ﬁbrosis. Our major ﬁnding
was an increase of the receptor Flt-1 at protein level in IPF in
comparison with sarcoidosis. Although the increase in VEGF
in IPF patients has not been conﬁrmed at the posttranscrip-
tional analysis, this may be due to high variation in the small
group of patients analyzed. In order to further investigate the
angiogenetic balance between granulomatous and ﬁbrotic
disorders, we measured CXC chemokines’ receptors and the
biological axis of CXCL12/CXCR4. Our major ﬁnding is the
signiﬁcant increase in CXCL12α in sarcoidosis’ patients in
comparison with IPF.
Recent immunological advances on sarcoidosis have
revealed a T helper 1 (Th1) and T helper 2 (Th2)
paradigm with predominance of the Th1 response in the
immunopathogenesis of sarcoidosis [20, 21]. The concept of
disparate activity of the IFN-γ-induced CXC chemokines in
the context of Th1-like immune disorders, such as sarcoido-
sis, was originally raised by Agostini et al. who documented
an enhanced expression of IP-10 in sarcoid tissues and a
positive relationship of BALF IP-10 levels and the degree
of T-cell alveolitis, suggesting its pivotal role in ruling the
migration of T-cells to sites of ongoing inﬂammation [22].
Our study group has recently showed a shift versus local Th1
immunologic response in sarcoidosis expressed by upregula-
tion of two major Th1cytokines, IL-12 and IL-18 [23–25].
In addition, we have further supported the assertion that
IFN-γ-induced CXC chemokines are strongly involved in
the immunomodulatory cascade of sarcoidosis implicating
angiostasis with Th1 immune response [12]. However, in the
current study, the distinct angiostatic proﬁle expressing by
CXCR3 between IPF and sarcoidosis did not reach statistical
signiﬁcance. In addition, Miotto et al. [26]d e s c r i b e da
speciﬁc for Th1-mediated response upregulation of IP-10
BALF levels further implicating angiostatic CXC chemokines
in the inﬂammatory cascade of sarcoidosis. Recently, Katoh
et al. reported elevated BALF concentrations of IP-10 and
MIG in patients with sarcoidosis and chronic eosinophilic
pneumonia [27]. Recent data in a large sarcoid population
suggest that CXCL9 and CXCL11 are important mediators in
recruiting CXCR3-expressing cells [28]. Importantly, it has
been shown that both lymphocytes and cells of monocyte
lineage express CXCR3 and are involved in the formation of
sarcoid lung granulomas [28].
Furthermore, Sekiya et al. [29] demonstrated a strong
correlation of elevated VEGF serum levels with clinical
parameters of disease activity in sarcoidosis patients indicat-
ing a potential usefulness as a predictor of disease activity
and responsiveness to treatment. In contrast BAL ﬂuid
VEGF levels from sarcoidosis patients were signiﬁcantly
lower than normal controls as reported by Koyama et al.
[30]. Low VEGF levels in the lung environment may reduce
angiogenesis and induce apoptosis of vascular endothelial
cells thus contributing to the pathogenesis of pulmonary
sarcoidosis. It has also been suggested that IP-10 may act
as a major chemotactic factor for lymphocytes and ENA-
78 as a ﬁbrogenic factor, and serum IP-10 levels were more
indicative of extrapulmonary lesions [30]. In the current
study, we detected an increase of CXCL12α and its speciﬁc
receptor, CXCR4, in pulmonary sarcoidosis, in comparison
with IPF and controls, respectively, suggesting its major
chemotactic role for lymphocytes, in accordance with the
aforementioned recent and previous data [28, 31].
However, there are several arguments that should be
addressed. First of all, we have the small number of patients
included in the study; moreover, there is the limitation of
several variations regarding the age, disparity of number
of males versus females in each group, smoking status,
pulmonary function tests, and BALF cell diﬀerentiation
between the diﬀerent disease groups and healthy subjects.
Secondly, this study is not a morphological one like other
elegant reports in lung tissue [32–35]. On the other hand,
t h i si sc u r r e n t l yd i ﬃcult, as the use of lung biopsy for the
diagnostic approach of sarcoidosis is limited. In addition, it
would be interesting to evaluate the angiogenetic process in
diﬀerent sarcoidosis stages.
In line with these ﬁndings, our study group demon-
strated a distinct local angiogenic proﬁle in patients with
IPF compared to sarcoidosis patients. The latter evidence
implicates angiogenesis in the ﬁbrotic (Th2) pathway of
ILDsandhighlightsnovelnoninvasivebiomarkerstoidentify
patients who are likely to develop progressive disease allow-
ing anti-inﬂammatory and other treatments to be evaluated
or eventually modiﬁed before they have failed. However,
further studies are needed in order to better investigate these
enigmatic diseases.
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